Esperion Therapeutics, Inc. Exhibit
EX-99.1 2 a18-14203_1ex99d1.htm EX-99.1 Exhibit 99.1     Media Contact: Elliot Fox W2O Group 212.257.6724 [email protected]   Investor Contact: Alex Schwartz Esperion 734-249-3386 [email protected]   Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid  Meets Primary Endpoint   — Study 3 Achieves Additional 26% LDL-C Lowering on Background of Maximally Tolerated LDL-C Lowering Therapy in Patients Considered Statin Intolerant — — Additional hsCRP Reduction of 25% — — Cumulative Phase 2 / Phase 3 Demonstrates Broad Efficacy as well as Safety and Tolerability — — Conference Call and Webcast on Wednesday,…
To view the full exhibit click here

About Esperion Therapeutics,Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.